The label for the achondroplasia drug, which promotes endochondral bone growth, now covers children under five years of age with the rare genetic disease causing the most common form of dwarfism.
Tag Archive for: achondroplasia
The rare disease biotech announced the FDA has accepted its supplemental New Drug Application to expand Voxzogo (vosoritide) to children younger than five years.
Rare disease biotech BioMarin Pharmaceuticals Inc. announced Friday it was shedding around 4% of its global workforce, or around 120 jobs, in an effort to improve its operational efficiency.
